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Abstract
Rationale Stress-related disorders are associated with dys-
function of both serotonergic and GABAergic pathways,
and clinically effective anxiolytics act via both neurotrans-
mitter systems. As there is evidence that the GABAA and
the serotonin receptor system interact, a serotonergic
component in the anxiolytic actions of benzodiazepines
could be present.
Objectives The main aim of the present study was to
investigate whether the anxiolytic effects of (non-)selective
α subunit GABAA receptor agonists could be reversed with
5-HT1A receptor blockade using the stress-induced hyper-
thermia (SIH) paradigm.
Results The 5-HT1A receptor antagonist WAY-100635
(0.1–1 mg/kg) reversed the SIH-reducing effects of the
non-α-subunit selective GABAA receptor agonist diazepam
(1–4 mg/kg) and the GABAA receptor α3-subunit selective
agonist TP003 (1 mg/kg), whereas WAY-100635 alone was
without effect on the SIH response or basal body
temperature. At the same time, co-administration of WAY-
100635 with diazepam or TP003 reduced basal body
temperature. WAY-100635 did not affect the SIH response
when combined with the preferential α1-subunit GABAA
receptor agonist zolpidem (10 mg/kg), although zolpidem
markedly reduced basal body temperature.
Conclusions The present study suggests an interaction
between GABAA receptor α-subunits and 5-HT1A receptor
activation in the SIH response. Specifically, our data
indicate that benzodiazepines affect serotonergic signaling
via GABAA receptor α3-subunits. Further understanding of
the interactions between the GABAA and serotonin system
in reaction to stress may be valuable in the search for novel
anxiolytic drugs.
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Introduction
Stress-related disorders are associated with dysfunction of both
serotonergic and GABAergic pathways (Akimova et al. 2009;
Kalueff and Nutt 2007; Nemeroff 2003). The clinical
anxiolytic effects of selective serotonin reuptake inhibitors,
5-HT1A receptor agonists and GABAA receptor agonists,
indicate that both the GABAAergic as well as theserotonergic
system may be involved in the pathological basis underlying
anxiety disorders (Nutt 2005; Zohar and Westenberg 2000).
There is evidence that the GABA and the serotonergic system
interact (Fernandez-Guasti and Lopez-Rubalcava 1998; Gao et
al. 1993; Lista et al. 1989), although the evidence whether it
plays a role in the stress response is inconsistent (Shephard et
al. 1982;T h i e b o t1986). Specifically, a serotonergic compo-
nent in the anxiolytic actions of benzodiazepines has been
suggested (Harandi et al. 1987;S t e i ne ta l .1977; Thiebot et
al. 1984). Hence, studying the interactions of the GABAA and
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Here, we investigate whether the anxiolytic effects of
GABAA receptor agonists are dependent on 5-HT1A
receptor activation using the stress-induced hyperthermia
(SIH) paradigm. The SIH response is the transient rise in
body temperature in response to acute stress that is
mediated by the autonomic nervous system (Bouwknecht
et al. 2007; Vinkers et al. 2008). Both classical benzodia-
zepines and 5-HT1A receptor agonists consistently reduce
the SIH response (as well as basal body temperature at
higher doses), whereas dopaminergic and noradrenergic
systems are generally ineffective (Olivier et al. 2003).
Classical (non-subunit selective) benzodiazepines bind to
GABAA receptor α1-, α2-, α3-, or α5-subunits, and the
various benzodiazepine effects are thought to be mediated
through different GABAA receptor subtypes (Rudolph and
Mohler 2006). Interactions with the serotonergic system
may thus depend on the GABAA receptor composition. In
the present study, we investigated whether the silent 5-
HT1A receptor antagonist WAY-100635 (WAY) could alter
the SIH-reducing and hypothermic effects of the non-
subunit selective GABAA receptor agonist diazepam, the
selective GABAA receptor α3-subunit agonist TP003 (Dias
et al. 2005), and the preferential GABAA receptor α1-
subunit agonist zolpidem.
Materials and methods
Animals
Eighty-four male NMRI mice (Charles River, The Netherlands)
were housed in Macrolon type 3 cages enriched with
bedding and nesting material under a 12-h light/12-h dark
cycle (lights on from 0600 to 1800 hours) at controlled
temperature (22±2°C) and relative humidity (40–60%) with
free access to standard food pellets and tap water. Experi-
ments were carried out with approval of the ethical
committee on animal experiments of the Faculties of
Sciences, Utrecht University, The Netherlands, and in
accordance with the Declaration of Helsinki.
The stress-induced hyperthermia (SIH) procedure
The SIH tests were carried out one time per week according
to standard procedures (Groenink et al. 2009). A between-
subject design was used, and animals were randomly
allocated to an experimental group. Cages were randomly
and evenly allocated over daytimes (morning to afternoon).
The temperature of mice was measured by rectally inserting
a thermistor probe by a length of 2 cm. Digital temperature
recordings were obtained with an accuracy of 0.1°C using a
Keithley 871A digital thermometer (NiCr–NiAl thermo-
couple). The probe, dipped into silicon oil before inserting,
was held in the rectum until a stable rectal temperature had
been obtained for 20 s. Animals were injected intra-
peritoneally with vehicle or WAY-100635 on the left flank
and with vehicle, diazepam, zolpidem, or TP003 on the
right flank. All drugs were injected 60 min before the first
temperature measurement (T1). This first temperature mea-
surement, representing the basal body temperature, functioned
as an adequate stressor as well. The temperature was again
measured 10 min later (T2), representing the stress-induced
body temperature. The SIH response was calculated by
subtracting T1 from T2.
Drugs
Diazepam (base), zolpidem (tartaric acid), and WAY-100635
(maleate) (N-{2-[4-(2-methoxyl)-1-piperazinyl]ethyl}-N-
(2-pyridinyl) cyclohexanecarboxamide tri-chloride) were
obtained from Sigma Aldrich. TP003 was synthesized
according to published methods (Dias et al. 2005;
Humphries et al. 2006). An injection volume of 10 ml/kg
was used for intraperitoneal injections of all drugs. WAY-
100635 was dissolved in saline. Diazepam, zolpidem, and
TP003 were suspended in gelatin–mannitol 0.5%/5%.
Fresh solutions and suspensions were prepared each testing
day. Doses of TP003 and zolpidem were based on previous
SIH studies (Dias et al. 2005; Olivier et al. 2002, 2003).
Data analysis
All experiments were carried out using a between-subject
design. For each individual mouse, a basal temperature (T1), an
end temperature (T2), and the difference (SIH response=T2−
T1) were determined. Treatment effects were evaluated using
a two-way analysis of variance with explanatory factors drug1
(WAY-100635 or vehicle) and drug2 (diazepam/zolpidem/
TP003 or vehicle). In addition, a post-hoc analysis was carried
out comparing diazepam/zolpidem/TP003 with vehicle under
both WAY-100635 and vehicle conditions using a Tukey's
Honestly Significant Difference (HSD) test. A probability
level of p<0.05 was set as statistically significant.
Results
Effects on the stress-induced hyperthermia response
Diazepam 1 mg/kg and WAY-100635 (n =8–9)
WAY-100635 (WAY) significantly reversed the diazepam
effect on the SIH response at all three WAY doses tested
(WAY 0.1 mg/kg, WAY×diazepam interaction, F1,31=5.02,
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F1,31=4.71, p<0.05; WAY 1.0 mg/kg, WAY×diazepam
interaction, F1,32=5.76, p<0.05; Fig. 1a). Post-hoc analysis
showed that diazepam reduced the SIH response when it
was co-administered with vehicle in one out of three
experiments (veh-veh vs. diazepam-veh: WAY 0.1 mg/kg,
p<0.05; WAY 0.3 mg/kg, p=0.53, NS; WAY 1.0 mg/kg,
p=0.17, NS), but that WAY altered the diazepam-induced
reduction of the SIH response (diazepam-veh vs. diazepam-
WAY: WAY 0.1 mg/kg, p<0.01; WAY 0.3 mg/kg, p<0.05;
WAY 1.0 mg/kg, p<0.01). In contrast, diazepam had no
effects when it was combined with WAY (veh-WAY vs.
diazepam-WAY: WAY 0.1 mg/kg, p=0.77, NS; WAY
0.3 mg/kg, p=0.10, NS; WAY 1.0 mg/kg, p=0.61, NS).
Diazepam 4 mg/kg and WAY-100635 (n=8–10)
WAY significantly reversed the diazepam effects on the SIH
response at higher doses (WAY 0.3 mg/kg, WAY×diazepam
interaction, F1,32=3.88, p=0.05; WAY 1.0 mg/kg, WAY×
diazepam interaction, F1,36=4.74, p<0.05; Fig. 1b). In
contrast, WAY did not alter the diazepam effects at the lowest
dose (WAY 0.1 mg/kg, WAY×diazepam interaction, F1,35=
1.20, p=0.28, NS). Post-hoc analysis showed that diazepam
reduced the SIH response when co-administered with vehicle
(veh-veh vs. diazepam-veh: WAY 0.1 mg/kg, p<0.01; WAY
0.3 mg/kg, p<0.05; WAY 1.0 mg/kg, p<0.01),andthatWAY
altered the diazepam-induced reduction of the SIH response at
the highest dose (diazepam-veh vs. diazepam-WAY:W A Y
Veh WAY 0.3 Veh WAY 1.0 Veh WAY 0.1
S
I
H
 
r
e
s
p
o
n
s
e
 
(
°
C
)
0,0
0,5
1,0
1,5
2,0
Vehicle
Diazepam 1 mg/kg A
*
*
Veh WAY 0.3 Veh WAY 1.0 Veh WAY 0.1
S
I
H
 
r
e
s
p
o
n
s
e
 
(
°
C
)
0,0
0,5
1,0
1,5
2,0
Vehicle
Diazepam 4 mg/kg
B
Veh WAY 0.3 Veh WAY 1.0 Veh WAY 0.1
S
I
H
 
r
e
s
p
o
n
s
e
 
(
°
C
)
0,0
0,5
1,0
1,5
2,0
Vehicle
TP003 1 mg/kg C
*
*
Veh WAY 0.3 Veh WAY 1.0 Veh WAY 0.1
S
I
H
 
r
e
s
p
o
n
s
e
 
(
°
C
)
0,0
0,5
1,0
1,5
2,0
Vehicle
Zolpidem 10 mg/kg
D
*
*
*
*
* * *
*
*
*
*
* *
# # #
#
*
#
#
#
Fig. 1 Effects of (a, b) diazepam (1 and 4 mg/kg, IP, n=8–10), (c)
TP003 (1 mg/kg, IP, n=7–10), and (d) zolpidem (10 mg/kg, IP, n=8–
10) administration in combination with WAY-100635 (0.1–1 mg/kg,
IP) or vehicle on the stress-induced hyperthermia (SIH) response.
Asterisk (*), p<0.05: drug effect compared to corresponding vehicle;
number sign (#), p<0.05: drug effect under vehicle vs. WAY
conditions
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1.0 mg/kg, p<0.05). Diazepam did not reduce the SIH
response combined with WAY (veh-WAY vs. diazepam-WAY:
WAY 0.1 mg/kg, p=0.06, NS; WAY 0.3 mg/kg, p=0.98, NS;
WAY 1.0 mg/kg, p=0.74, NS).
TP003 (1 mg/kg) and WAY-100635 (n=7–10)
WAY influenced the TP003 effect on the SIH response at
the lower WAY doses (WAY 0.1 mg/kg, WAY×TP003
interaction, F1,30=4.56, p<0.05; WAY 0.3 mg/kg, WAY×
TP003 interaction, F1,30=4.87, p<0.05; WAY 1.0 mg/kg,
WAY×TP003 interaction, F1,31=3.38, p=0.06, NS;
Fig. 1c). Post-hoc analysis showed that TP003 reduced
the SIH response when co-administered with vehicle in one
out of three experiments (veh-veh vs. TP003-veh:W A Y
0.1 mg/kg, p=0.11, NS; WAY 0.3 mg/kg, p<0.05; WAY
1.0 mg/kg, p=0.27, NS). However, WAYaltered the TP003
effects on the SIH response (TP003-veh vs. TP003-WAY:
WAY 0.1 mg/kg, p<0.01; WAY 0.3 mg/kg, p<0.05; WAY
1.0 mg/kg, p<0.05). In contrast, TP003 did not alter the
SIH response combined with WAY (veh-WAY vs. TP003-
WAY: WAY 0.1 mg/kg, p=0.52, NS; WAY 0.3 mg/kg, p=
0.77, NS; WAY 1.0 mg/kg, p=0.47, NS).
Zolpidem 10 mg/kg and WAY-100635 (n=8–10)
Zolpidem did not affect the SIH response in all three
experiments (WAY 0.1 mg/kg, zolpidem effect, F1,32=0.77,
p=0.39, NS; WAY 0.3 mg/kg, zolpidem effect, F1,31=0.30,
p=0.87, NS; WAY 1 mg/kg, zolpidem effect, F1,32=0.72, p=
0.40, NS; Fig. 1d). WAY did not change the zolpidem effects
at any dose (WAY 0.1 mg/kg, WAY×zolpidem interaction
F1,32=0.001,p=0.94, NS; WAY 0.3 mg/kg, WAY×zolpidem
interaction, F1,31=1.63, p=0.21, NS; WAY 1 mg/kg, WAY×
zolpidem interaction, F1,32=0.29, p=0.59, NS). Post-hoc
analysis indicated that zolpidem did not reduce the SIH
response, regardless whether it was co-administered with
vehicle (veh-veh vs. zolpidem-veh: WAY 0.1 mg/kg, p=0.95,
NS; WAY 0.3 mg/kg, p=0.99, NS; WAY 1.0 mg/kg, p=0.97,
NS) or with WAY (veh-WAY vs. zolpidem-WAY:W A Y
0.1 mg/kg, p=0.90, NS; WAY 0.3 mg/kg, p=0.76, NS;
WAY 1.0 mg/kg, p=0.72, NS).
Effects on basal body temperature
Diazepam 1 mg/kg and WAY-100635 (n=8–9)
At higher doses, WAY appeared to enhance the
temperature-reducing effects of diazepam (WAY 0.1 mg/
kg, WAY×diazepam interaction, F1,31=0.23, p=0.63, NS;
WAY 0.3 mg/kg, WAY×diazepam interaction, F1,31=4.40,
p<0.05; WAY 1.0 mg/kg, WAY×diazepam interaction,
F1,32=3.43, p=0.07; Fig. 2a). Post-hoc analysis confirmed
that diazepam reduced basal body temperature combined
with WAY at higher doses (veh-WAY vs. diazepam-WAY:
WAY 0.1 mg/kg, p=0.31, NS; WAY 0.3 mg/kg, p<0.01;
WAY 1.0 mg/kg, p<0.01) and that WAY enhanced the
diazepam effects on basal body temperature at higher doses
(diazepam-veh vs. diazepam-WAY: WAY 0.1 mg/kg, p=
0.80, NS; WAY 0.3 mg/kg, p<0.01; WAY 1.0 mg/kg, p<
0.05). In contrast, diazepam did not reduce basal body
temperature when co-administered with vehicle (veh-veh
vs. diazepam-veh: WAY 0.1 mg/kg, p=0.73, NS; WAY
0.3 mg/kg, p=0.96, NS; WAY 1.0 mg/kg, p=0.12, NS).
Diazepam 4 mg/kg and WAY-100635 (n=8–10)
WAY enhanced the effect of diazepam on basal body
temperature at higher doses (WAY 0.1 mg/kg, WAY×
diazepam interaction, F1,35=0.91, p=0.35, NS; WAY
0.3 mg/kg, WAY×diazepam interaction, F1,32=4.86, p<
0.05; WAY 1 mg/kg, WAY×diazepam interaction, F1,36=
18.47, p<0.001; Fig. 2b). Post-hoc analysis showed that
diazepam reduced basal body temperature when it was
combined with WAY (veh-WAY vs. diazepam-WAY:W A Y
0.1 mg/kg, p<0.001; WAY 0.3 mg/kg, p<0.001; WAY
1.0 mg/kg, p<0.001), and that WAYenhanced the diazepam
effects on basal body temperature at the highest WAY dose
(diazepam-veh vs. diazepam-WAY: WAY 0.1 mg/kg, p=
0.21, NS; WAY 0.3 mg/kg, p=0.20, NS; WAY 1.0 mg/kg,
p<0.001). In contrast, diazepam did not reduce basal body
temperature when it was co-administered with vehicle in
two out of three experiments (veh-veh vs. diazepam-veh:
WAY 0.1 mg/kg, p<0.01; WAY 0.3 mg/kg, p=0.37, NS;
WAY 1.0 mg/kg, p=0.65, NS).
TP003 (1 mg/kg) and WAY-100635 (n=7–10)
WAYaltered the effects of TP003 on basal body temperature
at all WAY doses tested (WAY 0.1 mg/kg, WAY×TP003
interaction, F1,30=4.54, p<0.05; WAY 0.3 mg/kg, WAY×
TP003 interaction, F1,30=9.01, p<0.01; WAY 1 mg/kg,
WAY×TP003 interaction, F1,31=4.28, p<0.05; Fig. 2c).
Post-hoc analysis showed that TP003 reduced basal body
temperature when it was combined with WAY in two out
of three experiments (veh-WAY vs. TP003-WAY:W A Y
0.1 mg/kg, p=0.13, NS; WAY 0.3 mg/kg, p<0.05; WAY
1.0 mg/kg, p<0.05) and that the TP003-WAY combination
reduced basal body temperature compared to the TP003-
vehicle combination (TP003-veh vs. TP003-WAY:W A Y
0.1 mg/kg, p<0.01; WAY 0.3 mg/kg, p=0.06, NS; WAY
1.0 mg/kg, p<0.05). In contrast, TP003 did not reduce basal
body temperature when co-administered with vehicle (veh-
veh vs.T P 0 0 3 - v e h : WAY 0.1 mg/kg, p=0.87, NS; WAY
0.3 mg/kg, p=0.47, NS; WAY 1.0 mg/kg, p=0.91, NS).
126 Psychopharmacology (2010) 211:123–130Zolpidem 10 mg/kg and WAY-100635 (n=8–10)
In all experiments, zolpidem reduced basal body tem-
perature (WAY 0.1 mg/kg, zolpidem effect, F1,32=25.07,
p<0.001; WAY 0.3 mg/kg, zolpidem effect, F1,31=136.20,
p<0.001; WAY 1 mg/kg, zolpidem effect, F1,32=41.39, p<
0.001; Fig. 2d). WAY did not alter the zolpidem effects on
body temperature (WAY 0.1 mg/kg, WAY×zolpidem
interaction, F1,32=0.01, p=0.98, NS; WAY 0.3 mg/kg,
WAY×zolpidem interaction, F1,31=0.38, p=0.54, NS;
WAY 1 mg/kg, WAY×zolpidem interaction, F1,32=2.28,
p=0.14, NS). Post-hoc analysis indicated that zolpidem
reduced basal body temperature, regardless whether it was
co-administered with vehicle (WAY 0.1 mg/kg, p<0.01;
WAY 0.3 mg/kg, p<0.01; WAY 1.0 mg/kg, p<0.05) or with
WAY (WAY 0.1 mg/kg, p<0.01; WAY 0.3 mg/kg, p<
0.001; WAY 1.0 mg/kg, p<0.01). Furthermore, WAY did
not alter the zolpidem effect on basal body temperature
(zolpidem-veh vs. zolpidem-WAY: WAY 0.1 mg/kg, p=0.56,
NS; WAY 0.3 mg/kg, p=0.43, NS; WAY 1.0 mg/kg, p=
0.07, NS).
Discussion
The present study investigated putative GABA-serotonin
interactions using the SIH paradigm. Our main finding is
that the non-selective GABAA receptor agonist diazepam
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Fig. 2 Effects of (a, b) diazepam (1 and 4 mg/kg, IP, n=8–10), (c)
TP003 (1 mg/kg, IP, n=7–10), and (d) zolpidem (10 mg/kg, IP, n=8–
10) administration in combination with WAY-100635 (0.1–1 mg/kg,
IP) or vehicle on basal body temperature. Asterisk (*), p<0.05: drug
effect compared to corresponding vehicle; number sign (#), p<0.05:
drug effect under vehicle vs. WAY conditions
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no longer reduced the SIH response and augmented
hypothermia in the presence of the 5-HT1A receptor
antagonist WAY-100635, suggesting an interaction between
the activation of the GABAA receptor α3-subunits and 5-
HT1A receptors. In contrast, WAY-100635 did not have any
effect when it was combined with the preferential α1-subunit
GABAA receptor agonist zolpidem. As WAY-100635 has no
affinity for GABAA receptors (Fletcher et al. 1996), our data
suggest that in the SIH paradigm, anxiolytic effects of
GABAA receptor agonists may be mediated via the serotonin
system. Thus, benzodiazepines may affect serotonergic
signaling via α3-subunits on a distinct group of serotonergic
neurons. In support, the vast majority of serotonergic neurons
express GABAA receptor α3-subunit immunoreactivity but
not GABAA receptor α1-subunit staining (Gao et al. 1993).
This is remarkable as the α1-subunit is highly prevalent in the
central nervous system.
The effects of the GABAergic drugs diazepam, TP003,
and zolpidem on the SIH response and body temperature
are generally in line with earlier SIH studies (Olivier et al.
2002; Vinkers et al. 2008, 2009). Diazepam effects on basal
body temperature slightly varied over the experiments,
which may be attributed to fluctuations in body temperature
under vehicle conditions due to physiological variance,
differences in environmental temperature, or the time of
testing. Classical non-selective benzodiazepines enhance
the inhibitory actions of GABA by binding to an allosteric
site on GABAA receptors that contain α1-, α2-, α3-, or α5-
subunits in combination with a β and a γ2 subunit
(Rudolph and Mohler 2006). Zolpidem is approximately
five- to tenfold more selective for α1-subunit-containing
GABAA receptors than α2/α3-subunit-containing receptors
(Petroski et al. 2006), whereas TP003 is α3-subunit
selective with low modulation via α1-, α2-, and α5-
containing subtypes (Dias et al. 2005). Recently, genetic
and pharmacological evidence has indicated that α-subunits
may differentially contribute to the various classical
benzodiazepine-induced effects such as anxiolysis, depen-
dence, anticonvulsant activity, sedation, and amnesia
(Crestani et al. 2001; Rudolph et al. 1999). Here, we
confirm and extend our earlier findings suggesting a role
for the GABAA receptor α1 subunit in hypothermia and a
role for the GABAA receptor α2/3 subunit in reduction of
the SIH response (Vinkers et al. 2009).
In the present study, WAY-100635 did not affect the SIH
response in any of the experiments when it was adminis-
tered alone which is in line with earlier studies (Olivier et
al. 2003, 2008). The 5-HT1A receptor antagonist WAY-
100635 is generally assumed to act as silent antagonist but
has also been reported to exert anxiolytic or even
anxiogenic effects depending on the experimental design
(Cao and Rodgers 1997; Fletcher et al. 1996; Forster et al.
1995; Griebel et al. 2000; Groenink et al. 1996; Joordens et
al. 1998; Stanhope and Dourish 1996). WAY-100635 has
also been shown to reverse the SIH-reducing effects of 5-
HT1A receptor agonists such as buspirone and flesinoxan,
confirming that WAY-100635 targets 5-HT1A receptors
(Iijima et al. 2007; Olivier et al. 1998). Interestingly,
WAY-100635 has also been able to reverse the SIH
reduction caused by the mGluR2/3 receptor antagonist
MGS0039, suggesting that the 5-HT1A receptors may also
be involved in the effects of glutamate receptor antagonists
(Iijima et al. 2007).
WAY-100635 could reverse the α3-induced effects in the
SIH paradigm by blocking presynaptic 5-HT1A receptors
that disinhibit serotonin release and turnover at synaptic
levels (Wesolowska et al. 2003), which may then activate
postsynaptic 5-HT receptors. Electrophysiological studies
show that WAY-100635 increases serotonergic neuronal
a c t i v i t yp r o b a b l yb yb l o c k i n g5 - H T 1A autoreceptors
(Corradetti et al. 1996; Fornal et al. 1996; Mundey et al.
1996). In support, serotonergic raphe nuclei receive a
prominent GABAergic input via distant sources as well as
interneurons (Bagdy et al. 2000; Gervasoni et al. 2000;
Harandi et al. 1987; Varga et al. 2001). However, this can
only provide a partial explanation as WAY-100635 also
augmented the benzodiazepine-induced hypothermia, puta-
tively via an activation of α1-subunits (Vinkers et al. 2009).
Also, raphe lesions did not attenuate the anticonflict activity
of peripherally administered benzodiazepines, suggesting
that difficulties may exist in generalizing findings from one
paradigm to another (Green and Hodges 1986). Further-
more, it is striking that WAY-100635 reverses the SIH
response while it augments the hypothermia. It may be
hypothesized that GABAA–serotonin interactions relevant
for thermoregulation exist in the preoptic area or dorsome-
dial hypothalamus (Dimicco and Zaretsky 2007)o r ,
alternatively, that dorsal and median raphe projections
differentially affect basal and stress-induced body temper-
ature levels. In support, 5-HT was found to presynaptically
inhibit GABA release in the thermoregulatory hypothalam-
ic medial preoptic area, which could be blocked by a 5-
HT1A receptor antagonist (Lee et al. 2008). We also cannot
exclude the possibility that downstream activation of
hypothalamic 5-HT1A receptors, subsequent to the direct
activation of GABAA receptors, is needed to maintain the
core body temperature. Thus, detailed hypotheses on the
potential interactive sites of GABAA receptors and 5-HT1A
receptors and their functional relevance must await further
experimental analysis. Some studies have found decreased
serotonin activity and turnover after benzodiazepine ad-
ministration (Chase et al. 1970; Pratt et al. 1979; Stein et al.
1977; Trulson et al. 1982; Wright et al. 1992), although
others have not found such effects (Shephard et al. 1982;
Thiebot 1986; Thiebot et al. 1984). The present study used
128 Psychopharmacology (2010) 211:123–130the SIH paradigm as an anxiolytic assay as it can repeatedly
be used over the weeks without any habituation. However,
the use of a single paradigm prevents a direct generalization
of our results to other anxiolytic tests.
In conclusion, the present study shows that 5-HT1A receptor
blockade reversed the anxiolytic effects of the non-selective
GABAA receptor agonist diazepam and the α3-selective
GABAA receptor agonist TP003, whereas it enhanced
benzodiazepine-induced hypothermia. In contrast, these
effects were not present in combination with the preferential
GABAA receptor α1-subunit agonist zolpidem. Together,
these data suggest that the GABAA receptor α3-subunit
functionally interacts with 5-HT1A receptors of the serotonin
system to exert its anxiolytic effects in the SIH paradigm.
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